Corvus Pharmaceuticals, Inc. CRVS

Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biologySOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa. “The initiation of our Phase 1b hidrade

Corvus Pharmaceuticals (CRVS) has drawn fresh attention after recent trading left the biotech down about 19% over the past month and 13% over the past 3 months from a US$11.80 close. That recent slide sits against a much stronger ride for Corvus Pharmaceuticals, with the share price return still up 61.2% year to date and the 1 year total shareholder return at 78.52%, while the 3 year total shareholder return is very large at roughly 7x. This indicates strong long term momentum even as short...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the 2026 Cantor Global Healthcare Conference, which is being held in New York, NY. The fireside chat will be on Thursday, September 10, 2026 at 1:00 pm ET (10:00 am PT). A webcast of the fireside

Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (

On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company’s oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. That kind of breadth from a single-asset biotech is either a […]

Corvus Pharmaceuticals Inc (CRVS) reports robust financials and progresses key clinical trials for soquelitinib across multiple indications.

Moby summary of Corvus Pharmaceuticals, Inc.'s Q2 2026 earnings call

Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting Cash, cash equivalents and marketable securities of $215.2 million at June 30, 2026, providing runway into 2Q28 Co

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2026 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic

Corvus Pharmaceuticals (NasdaqGM:CRVS) reported promising Phase 1 results for its immunology drug candidate soquelitinib, with a favorable safety profile. The company has funding in place that it expects to last into Q2 2028, supporting further clinical development. Phase 2 data in atopic dermatitis for soquelitinib is anticipated, with investors watching for clarity on efficacy and future plans. These developments have led to discussion of Corvus Pharmaceuticals as a potential M&A target in...

Is CRVS a good stock to buy? We came across a bullish thesis on Corvus Pharmaceuticals, Inc. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on CRVS. Corvus Pharmaceuticals, Inc.’s share was trading at $11.15 as of June 8th. Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of […]

$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United StatesSOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Phar

This cloud-based payments provider delivers SaaS solutions to enterprise billers across utilities, finance, and healthcare sectors.

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wed